Abstract
As docetaxel is known to have significant antineoplastic activity against breast and ovarian cancer, we explored its application as a peripheral blood stem cell mobilizing agent in 33 women with stage lll–IV ovarian carcinoma (n = 10) or stage ll–lV breast cancer (n = 23) who were in preparation for high-dose chemotherapy. Eleven patients had bone and/or bone marrow involvement with their disease. The median number of prior regimens received before mobilization was two (range 1–3). The three dose levels administered were 100 mg/m2, 110 mg/m2 and 120 mg/m2. Patients received one dose of docetaxel in the outpatient setting followed by G-CSF (10 μg/kg/day) starting 4 days after docetaxel administration. Leukapheresis commenced when WBC >1.0 × 109/l or when the WBC began to rise after reaching a nadir. Ninety-seven percent of patients began leukapheresis within 7–9 days after receiving docetaxel (range 7–10 days). The collection goal was ⩾2 × 106 CD34+ cells/kg. Twenty-seven (82%) patients reached this goal in a median of 2 leukapheresis days (range 1–3). No grade 2–4 nonhematologic toxicities were noted. Thirteen patients (55%) showed a WBC nadir >1.0 × 109/l. None of the patients experienced neutropenic fever or required blood or platelet transfusion support. In conclusion, docetaxel + G-CSF is an effective, well-tolerated regimen for PBPC mobilization which can be safely administered in the outpatient setting with minimal toxicity. Bone Marrow Transplantation (2001) 27, 677–681.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Stadtmauer EA, Schneider CJ, Silberstein LE . Peripheral blood progenitor cell generation and harvesting Semin Oncol 1995 22: 291–300
Valero V, Holmes FA, Walters RS et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer J Clin Oncol 1995 13: 2886–2894
Burstein HJ, Manola J, Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer J Clin Oncol 2000 18: 1212–1219
Bonneterre J, Spielman M, Guastalla JP et al. Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience Eur J Cancer 1999 35: 1431–1439
Francis P, Schneider J, Hann L et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer J Clin Oncol 1994 12: 2301–2308
Kavanagh JJ, Kudelka AP, de Leon CG et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum Clin Cancer Res 1996 2: 837–842
Valero V, Jones SE, Von Hoff DD et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer J Clin Oncol 1998 16: 3362–3368
Burtness BA, Psyrri A, Rose M et al. A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells Bone Marrow Transplant 1999 23: 311–315
Klein JL, Rey PM, Dansey R et al. Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells Bone Marrow Transplant 1999 24: 959–963
Gomez-Espuch J, Moraleda JM, Ortuno F et al. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotherapeutic agent, associated with rhG-CSF Bone Marrow Transplant 2000 25: 231–235
Weaver CH, Schwartzberg LS, Birch R et al. Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer Biol Blood Marrow Transplant 1997 3: 83–90
Demirer T, Rowley S, Buckner CD et al. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer J Clin Oncol 1995 13: 1714–1719
Demirer T, Buckner CD, Storer B et al. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor J Clin Oncol 1997 15: 684–690
Pedrazzoli P, Perotti C, Prada GD et al. Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer Br J Cancer 1997 75: 1368–1372
Prince HM, Gardyn J, Millward MJ et al. Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer Bone Marrow Transplant 1999 23: 427–435
Borges VF, Jocye RM, Uhl L et al. Docetaxel and filgrastim provides a safe and effective mobilization regimen prior to high-dose chemotherapy for breast cancer Biol Blood Marrow Transplant 2000 6: 139 (Abstr.)
Prince HM, Toner GC, Seymour JF et al. Docetaxel effectively mobilizes peripheral blood CD34+ cells Bone Marrow Transplant 2000 26: 483–487
Hollingsworth KL, Zimmerman TM, Karrison T et al. The CD34+ cell concentration in peripheral blood predicts CD34+ yield in the leukapheresis product Cytotherapy 1999 1: 141–146
Elliott C, Samson DM, Armitage S et al. When to harvest peripheral blood stem cells after mobilization chemotherapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood J Clin Oncol 1996 14: 970–973
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Laport, G., Fleming, G., Waggoner, S. et al. A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer. Bone Marrow Transplant 27, 677–681 (2001). https://doi.org/10.1038/sj.bmt.1702861
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702861
Keywords
This article is cited by
-
Mobilization of peripheral blood stem cells using regimen combining docetaxel with granulocyte colony-stimulating factor in breast cancer patients
Chinese Journal of Cancer Research (2011)